Clinical Trial Update: Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab in cancers with mismatch repair deficiency has completed; results were posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematopoietic and Lymphoid Cell Neoplasm
• Lymphoma
• Malignant Solid Neoplasm
• Plasma Cell Myeloma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2021-04-06